| Code | CSB-RA017712MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to tovetumab, targeting platelet-derived growth factor receptor alpha (PDGFRA). PDGFRA is a receptor tyrosine kinase that plays a critical role in cellular proliferation, differentiation, and survival by binding platelet-derived growth factor (PDGF) ligands. Upon activation, PDGFRA initiates downstream signaling cascades including the PI3K/AKT and MAPK pathways, which regulate cell growth and migration. Aberrant PDGFRA signaling is implicated in various malignancies, including gastrointestinal stromal tumors (GIST), glioblastoma, and certain sarcomas, where activating mutations or overexpression drive oncogenic transformation and tumor progression.
Tovetumab is a therapeutic monoclonal antibody that selectively binds to PDGFRA, blocking ligand-receptor interaction and subsequent signaling activation. This biosimilar antibody serves as a valuable research tool for investigating PDGFRA-mediated pathways in cancer biology, studying receptor expression patterns in tumor samples, and exploring therapeutic mechanisms of PDGFRA inhibition. It enables researchers to examine the role of PDGFRA in disease models and evaluate potential therapeutic strategies targeting this receptor in oncology research.
There are currently no reviews for this product.